Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab + Bevacizumab + XELOX vs Placebo + Bevacizumab + XELOX in First-Line Metastatic Colorectal Cancer
jRCT2061240047Phase 3Active, not recruiting
- Sponsor
- Henlius
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in metastatic colorectal adenocarcinoma (mCRC) comparing Serplulimab + Bevacizumab + XELOX with Placebo + Bevacizumab + XELOX (2 arms). Primary endpoints: Progression-free survival (PFS) by IRRC and Overall survival (OS). Started Oct 2024; status: active, not recruiting.
02
Drugs
serplulimab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on jRCT2061240047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240047.